Kornimate/medical-research-clean huggingface dataset:
clinical study to compare cold snare underwater polypectomy to cold snare conventional polypectomy for colon polyps [coldwater study]

Conditions: Colon Polyps; Polypectomy

Summary: colon cancer is internationally the third cause of deaths from a malignant disease. screening colonoscopy in adults \>45 years of age aims at the early diagnosis and treatment colon polyps that are precancerous lesions. endoscopic polyp removal (polypectomy) can be done with various techniques depending on the size, morphology, location of the polyp etc. according to updated guidelines, non-pedunculated polyps of small size are treated with a cold snare in air dilated intestinal lumen (conventional cold snare polypectomy - ccsp).in recent years, several studies have described the benefits of water aided colonoscopy, as well as safety and efficacy of underwater polypectomy in large colon polyps. however, there is not enough data on small polyps which are the most commonly diagnosed.this is a prospective randomized double-blind clinical trial to compare the safety and efficacy of ccsp to underwater cold snare polypectomy (ucsp)for non-pedunculated polyps of size of 5-10 mm. a total of 398 polyps will be randomized and randomization will be performed via random numbers method of microsoft excel 2016. primary outcome of this study is to determine muscularis mucosa resection rate. secondary outcomes are the depth and percentage of r0 excisions and possible complications. the investigators expect ucsp to ensure a higher muscularis mucosa resection rate and they attempt to examine the resection depth in the submucosal layer.these results will provide useful data for the development of guidelines in polypectomy techniques for non-pedunculated polyps 5-10mm.


Eligibility criteria:
inclusion criteria: 1. age \> 20years 2. non pedunculated polyps (paris classification isp, is, iia, iib) 3. polyp size: diameter of 5 to 10mm 4. endoscopic diagnosis of mucosal lesions - must not present malignant submucosal infiltration evidence like deepening, ulceration / ulcer, abnormal vessels, irregular surface, (nice 1, nice 2a, basic) 5. informed consent 6. patients who receive antiplatelet / anticoagulant therapy are included in the study only if their therapy has been modified according to esge guidelines exclusion criteria: 1. age \<20 years old 2. pedunculated polyps 3. lesions with macroscopic elements of high-grade dysplasia or submucosal infiltration 4. sites with previous polypectomy 5. patients with idiopathic inflammatory bowel disease 6. patients with coagulation disorders 7. patients with severe organ failure 7.patients who during endoscopy will undergo any technique using electrocautery / electrocoagulation will not be eligible for participation in the study.

Keywords: colon polyps underwater polypectomy cold snare polypectomy polypectomy cold snare
markers of recovery in stroke study (morse)

Conditions: Stroke

Summary: our current biological understanding of stroke recovery in humans is extremely limited and this lack of knowledge is a major challenge in reducing stroke disabilities and deficits. evidence of neural repair in humans can be gleaned indirectly through functional outcome measures, but we propose that metabolomics may also provide a minimally invasive window into human brain repair. this study will integrate clinical imaging and molecular biomarkers as a diagnostic tool in further understanding stroke recovery mechanisms.

our long-term goal is to improve and hasten recovery following a stroke with translational research, which would combine the use of neuroimaging and identify neural repair metabolites. the objective and sequential step in fulfilling our long-term goal, is to identify differential expression of select stroke plasma biomarkers of neural repair, and image cst integrity in patients with good and poor recovery following an ischemic stroke. diffusion tension imaging (dti), will be used to image the neural repair as it occurs, further enhancing our understanding of stroke recovery. there are currently no known plasma biomarkers of neural repair. identification of such biomarkers would be extremely valuable for designing stroke recovery drugs and timing rehabilitation therapies.

Eligibility criteria:
inclusion criteria: * imaging confirmed ischemic stroke within 7 days of stroke onset * age \> 18 years * nihss ≥ 1 on arm item or nihss = 0 on arm item but \< 3/5 strength on mrc scale in distal joint (flex/ext elbow or grip/ext hand) * pre-stroke modified rankin scale (mrs) \< 3 exclusion criteria: * active malignancy (not thought to be cured or in remission) * anemia (hct \< 25) * sepsis * suspected bacterial endocarditis
meta-analysis of soluble fiber consumption on body weight, glycemia, and insulinemia in overweight and obese adults.

Conditions: Obesity

Summary: dietary fiber intake is protective against overweight and obesity; however, a significant fiber gap exists between consumption and recommended intake values. soluble fiber beneficially impacts metabolism, and supplementation may be a feasible approach to improve body composition and glycemia in overweight and obese individuals. the investigators will evaluate results of randomized controlled trials (rcts) of soluble fiber supplementation among overweight and obese adults for outcomes related to weight management (e.g. body mass index \[bmi\], body weight, body fat percentage, waist circumference) and glucose and insulin homeostasis (e.g. fasting glucose, homeostasis model assessment of insulin resistance \[homa-ir\], fasting insulin) through systematic review and meta-analysis.


Eligibility criteria:
inclusion criteria: peer-reviewed randomized controlled trials (rcts) will be included in the systematic review and meta-analysis if they involve participants who are: 1. overweight or obese (bmi ≥ 25.0 kg/m2 for u.s. populations and ≥ 23.0 kg/m2 for asian populations and/or waist circumference ≥ 40 inches (94 cm) in men or ≥ 35 inches (80 cm) in women and/or waist-to-hip ratio ≥ 0.90 in men or ≥ 0.85 in women). 2. weight stable and not actively trying to lose weight at screening. 3. without physician-diagnosed chronic conditions at screening (e.g., dyslipidemia, hypertension, type 2 diabetes, and cardiovascular disease). 4. included studies will be soluble fiber supplementation interventions that are controlled feeding studies or conducted among free-living subjects that provide data for outcomes of interest. exclusion criteria: studies will be excluded from the systematic review and meta-analysis if they meet any of the following criteria: 1. studies conducted in animals. 2. mechanistic research. 3. human trials involving pregnant women, breastfeeding women, or children. 4. conference proceedings. 5. articles not published in english. 6. studies less than 1 week in duration. 7. studies that pool outcome measure data for healthy weight and overweight and obese individuals. 8. studies involving whole food treatments or high fiber profile diets. 9. weight loss interventions involving other tactics, such as counseling or energy restriction.

Keywords: dietary fiber soluble fiber body mass index body weight blood glucose insulin
central corneal thickness in glaucoma

Conditions: Exfoliation Syndrome

Summary: the purpose of this study is to compare the central corneal thickness measurement in patients with exfoliation syndrome, exfoliative glaucoma, primary open-angle glaucoma, ocular hypertension and normal controls and to evaluate the value of corneal thickness in the diagnosis and management of glaucoma.

to compare the central corneal thickness measurement in patients with exfoliation, primary open-angle glaucoma, ocular hypertension and normal controls and to evaluate the value of corneal thickness in the diagnosis and management of glaucoma. prospective study in progress. randomly selected patients undergo a comprehensive ophthalmic exam which includes 2 separate pachymetry measurements in 2 different examinations at the same time of the day (10:00 am) with 3 different pachymeters. the values obtained are correlated with a number of other glaucoma parameters. a thinner cornea may represent a specific attribute and an additional risk factor for patients with exfoliation. evaluation of corneal thickness is an important exam in the management of patients with exfoliation.

Eligibility criteria:
inclusion criteria: * exfoliation material on pupil * intraocular pressure below 21 mm hg without glaucomatous damage * intraocular pressure above 21 mm hg without glaucomatous damage * raised intraocular pressure with glaucomatous damage exclusion criteria: * corneal disorders * history of trauma * evidence of corneal abnormality that may influence iop * contact lens use * corneal surgery

Keywords: corneal thickness exfoliation
dimethylxanthenone acetic acid in treating patients with solid tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: dimethylxanthenone acetic acid may stop the growth of cancer cells by stopping blood flow to the tumor. purpose: phase i trial to study the effectiveness of dimethylxanthenone acetic acid in treating patients with solid tumors that have not responded to previous therapy.

objectives: i. determine the toxicity of dimethylxanthenone acetic acid (dmxaa) in patients with solid tumors. ii. establish a maximum tolerated dose for this drug in these patients. iii. determine the pharmacokinetics of dmxaa in these patients. iv. determine the effect of this regimen on coagulation parameters, tnf and other cytokine production, nitric oxide, and serotonin production in these patients. v. assess the efficacy of this drug in this patient population. vi. determine the effect of this drug on tumor vasculature by evaluating any changes apparent on mri scans in these patients. outline: this is a dose escalation, multicenter study. patients receive dimethylxanthenone acetic acid (dmxaa) iv over 20 minutes once weekly for 6 weeks, followed by 2 weeks of rest. an additional course of therapy may be administered in the absence of unacceptable toxicity or disease progression. cohorts of 3 patients receive escalated doses of dmxaa until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which 2 of 3 patients experience dose limiting toxicity. projected accrual: a minimum of 3 patients will be accrued to each dose level used to determine the maximum tolerated dose.

Eligibility criteria:
disease characteristics: histologically confirmed solid tumor that is not amenable to any standard therapy or is refractory to conventional therapy tumor mass larger than 3 cm accessible to mri scan documented progression within the past 2 months patient characteristics: age: 18 to 75 performance status: who 0-2 life expectancy: greater than 3 months hematopoietic: hemoglobin at least 9 g/dl wbc at least 3,000/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin less than 1.2 mg/dl alt less than 2 times upper limit of normal (uln) alkaline phosphatase less than 2 times uln renal: creatinine less than 1.5 mg/dl other: fertile patients must use effective contraception no concurrent malignancy except cone biopsied carcinoma in situ of the cervix and adequately treated basal or squamous cell carcinoma of the skin no other serious medical condition no uncontrolled infection or serious infection within the past 28 days must live within 1 hour of mount vernon hospital, uk prior concurrent therapy: at least 4 weeks since prior anticancer therapy (6 weeks for nitrosoureas and mitomycin) and recovered

Keywords: unspecified adult solid tumor, protocol specific
surgery for primary congenital glaucoma in neonates

Conditions: Primary Congenital Glaucoma

Summary: the current study aimed to compare between the long-term surgical outcomes of 3 surgical options (viscotrabeculotomy (vt), visco-circumferential-suture-trabeculotomy (vcst) or combined vt-trabeculectomy with mmc (vt-trab) in treatment of infants with (primary congenital glaucoma (pcg)) below 1 month of age.

this is a prospective, randomised controlled trial. we plan to recruit 60 infants with primary congenital glaucoma and younger than 1 month of age at the outpatient clinic of mansoura ophthalmic center of mansoura university in mansoura, egypt. eyes will be randomly assigned to undergo one of 3 surgical interventions: viscotrabeculotomy (vt), visco-circumferential-suture-trabeculotomy (vcst) or combined vt-trabeculectomy with mmc (vt-trab). the primary outcome of this study is compare the success rate in lowering iop between the 3 surgical options in infants with primary congenital glaucoma (pcg) below 1 month of age. the secondary clinical outcomes will include intraocular pressure (iop), horizontal corneal diameter, axial length, cup-disc ratio, refractive error and postoperative complications in these 3 surgical procedures. data will be analysed. complete success was defined as an iop from 5 to 16 mmhg (under general anesthesia), without antiglaucoma drugs (agd) or further surgical interventions, without progression of corneal diameter or disk cupping, and without serious visual complications. qualified success was defined as fulfilling the same criteria but with the use of agd.

Eligibility criteria:
inclusion criteria: primary congenital glaucoma in neonates exclusion criteria: secondary congenital glaucoma in neonates. congenital glaucoma presented after 1 month of age.
gross myofascial release in cervical radiculopathy pat

Conditions: Cervical Radiculopathy

Summary: to investigate the effect of gross myofascial release on pain and function in cervical radiculopathy patients. background: cervical radiculopathy is considered serious problems causing neck pain \& radiating pain which affect physical inactivity and function of a patient, thus gross myofascial release is a form of manual therapy technique that has a profound effect upon the musculoskeletal system. hypotheses: this study hypothesized that: gross myofascial release on pain and function in cervical radiculopathy patients research question: is there an effect of gross myofascial release on pain and function in cervical radiculopathy patients?

forty patients with cervical radiculopathy will participate in this study. the patients will randomly be divided into two equal groups; the control group which received the conventional selected exercise program and the study group received the same exercise training program in addition to gross myofascial release, three times per week for four weeks. the evaluation methods are visual analogue scale (vas), electro-goniometer, quick dash scale, and neck disability index

Eligibility criteria:
inclusion criteria: * 40 cervical radiculopathy patients, * age will range as (30:45) years old * cervical radiculopathy due to cervical spondylosis * body mass index (25:29) exclusion criteria: * difficulty to communicate or to understand program instructions * any other neurological deficits or orthopaedic abnormalities, * secondary musculoskeletal complication * cervical disc prolapses * any other cervical problem * spinal stenosis * previous spinal surgery
study of endostar combined with tp regimen for esophageal cancer

Conditions: Patients With Esophageal Cancer(Ⅱ-Ⅲ)

Summary: a randomized controlled trial of endostar combined with tp regimen(liposomal paclitaxel-carboplatin) for chemoradiotherapy in esophageal squamous cell carcinoma(ⅱ-ⅲ)

this study was a controlled clinical trial.a total of 402 patients with pathologically confirmed esophageal squamous cell carcinoma would be enrolled.patients were randomly divided into two group ,with 201 in the treatment group and 201 in the control group.the treatment group was treated with endostar,chemotherapy (liposomal paclitaxel-carboplatin)and concurrent radiotherapy.the control group was treated with chemotherapy (liposomal paclitaxel-carboplatin)and concurrent radiotherapy .the efficiency and safety would be evaluated. the objective response rate and progress free survival would be analyzed.this data of this study might provide a more effective treatment for esophageal squamous cell carcinoma

Eligibility criteria:
inclusion criteria: 1. aged 18 to 75 years; 2. pathology confirmed as esophageal squamous cell carcinoma and clinical stage is ii-iii; 3. initial treatment, no surgery history; 4. ecog 0\~2; 5. expected survival \>=3 months; 6. all the patients should have target lesions that are measurable and evaluable; 7. should be able to consume liquid diet, no esophageal perforation symptoms, no distant metastases; 8. the main organ function is normal, which meets the following criteria: (1) the standard of blood test should be met (14 days without blood transfusion and blood products, no g-csf and other hematopoietic stimulation factor correction): hb\>=100g/l;anc\>=1.5x10\^9/l;plt\>=100x10\^9/l; (2) biochemical inspection shall meet the following criteria: tbil \ 50 ml/min (the cockcroft gault formula); (3) pulmonary function fev1 \>=1 l or \>50% of corresponding value of normal people; 9. female during the reproductive period should be ensured contraception during the study period; 10. participants voluntarily joined the study, signed informed consent, and had good compliance and follow-up. exclusion criteria: 1. patients who do not meet the pathological type of the inclusion criteria and the primary site; 2. allergic to recombinant endostar, carboplatin, paclitaxel, and contrast agents; 3. have a distant metastasis; 4. the primary focal tumors or lymph node already had a surgical treatment (except for biopsy), chemoradiotherapy or targeted therapy; 5. patient who suffered from other malignant tumor; 6. subject with severe pulmonary and cardiopathic disease history; 7. pregnant woman or lactating women and women in productive age who refuse take contraception in observation period; 8. subject with a personality or psychiatric diseases, people with no legal capacity or people with limited capacity for civil conduct; 9. received other medicine trials in past 4 weeks; 10. refuse or incapable to sign the informed consent form of participating this trial; 11. the researchers judged other conditions that could affect clinical research and the results of the study.

Keywords: endostar esophageal cancer
epigenetics of posttraumatic stress disorder and somatoform disorders in the course of psychotherapy

Conditions: Psychiatric Disorder; Somatoform Disorders; PTSD

Summary: this reported observational clinical study aims at identifying epigenetic markers in a sample of patients undergoing high dose inpatient psychotherapy suffering from a variety of psychiatric/psychosomatic diseases such as somatoform disorders, posttraumatic stress disorder (ptsd), depression, anxiety disorders and eating disorders. the exact epigenetic markers that will be traced are yet to define. the investigators believe that 1. epigenetic patterns found in the group of psychiatric patients show differences from healthy controls 2. different diagnosis show differences in epigenetic patterns as well 3. epigenetic patterns correlate to the severity of the psychosocial disorder as measured in interviews or psychometric ratings 4. epigenetic patterns can change under inpatient high dose psychotherapy 5. changes correlate to clinical psychometric variables.


Eligibility criteria:
inclusion criteria: * informed consent given by the patient * adulthood to 65 years * stabel physical health * at least fluent in german language (as it is a group-therapy) exclusion criteria: * psychiatric disorder such as substance addiction, psychosis, schizophrenia. * insufficient understanding of the terms and conditions of the study * insufficient emotional stability to fill out the psychometric forms required for the study.

Keywords: somatoform disorders ptsd epigenetics psychotherapy psychosomatics
observational study to evaluate the safety of dilatrend sr cap. in korean patients with essential hypertension, chronic stable angina and congestive heart failure

Conditions: Essential Hypertension; Chronic Stable Angina; Congestive Heart Failure

Summary: the purpose of this study is to evaluate the safety of dilatrend sr cap. in korean patients with essential hypertension, chronic stable angina and congestive heart failure for 52 weeks.


Eligibility criteria:
inclusion criteria: 1. age 19 years or older patients with essential hypertension, chronic stable angina and congestive heart failure 2. possible to take dilatrend sr on the label 3. not taking caverdilol for 6 month from agreement date 4. agreement with written informed consent exclusion criteria: 1. pregnancy or lactation 2. known hypersensitivity to carvedilol 3. cardiogenic shock 4. abnormality of the conduction system as severe bradycardia(in particular, pulse \<50beats / min), 2nd degree av block, complete av block, sinus block, sick sinus syndrome 5. cor pulmonale 6. iddm with ketoacidosis, metabolic acidosis 7. has severe heart disease(heart failure nyha functional class 4) 8. respiratory diseases as asthma, chronic obstructive pulmonary disease 9. secondary hypertension 10. prinzmetal's angina 11. acute pulmonary embolism 12. pheochromocytoma 13. take mao lnhibitor(except for mao-b) 14. hypotension ( sbp 90mmhg or less) 15. severe hepatic dysfunction 16. peripheral circulatory disturbance( ex. raynaud syndrome, intermittent claudication) 17. has edema glottitis 18. has heart attack with complication 19. fluid retention or overload to required intravenous inotropes 20. allergic rhinitis

Keywords: carvedilol sr cap essential hypertension chronic stable angina congestive heart failure
post marketing observational study of retreatment of chronic hepatitis c with peginterferon alpha and ribavirin (study p06011)

Conditions: Hepatitis C, Chronic

Summary: to study retreatment in patients who failed prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin in a real-life setting in an observational/noninterventional study.

this is an observational/non interventional study to collect data on the patient characteristics of those seeking retreatment as well as safety and efficacy information during the first 12 weeks of retreatment.

Eligibility criteria:
inclusion criteria: * chronic hepatitis c of any genotype; * prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin did not result in a sustained virological response; * inclusion criteria listed on the approved label in each country; * willingness of the patient to participate and sign the informed consent form. exclusion criteria: * patient exclusion from this observational/non-interventional study will be determined by the treating physician and will be based on the local label in each country.